<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>An <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">Antiphospholipid syndrome</z:e> (APS) was diagnosed in a patient who had massive pulmonary embolisation from a right atrial <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The (APS) is an <z:hpo ids='HP_0002960'>autoimmune disease</z:hpo> defined by the presence in the serum of at least one type of autoantibody known as <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> (aPL) and the occurrence of at least one clinical feature from a list of potential disease manifestations, the most common of which are venous or <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo>, recurrent fetal loss and <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The prevalence of APS in a series of patients from internal medicine is 2 percent </plain></SENT>
<SENT sid="3" pm="."><plain>The mean age at diagnosis is 42 years </plain></SENT>
<SENT sid="4" pm="."><plain>The pathogenesis of APS associated with clinical manifestations seems to result from a variety of effects of aPL on coagulation pathways,but the exact mechanism of action of aPL on these pathways is not completely understood </plain></SENT>
<SENT sid="5" pm="."><plain>The APS can be primary or secondary to a disease </plain></SENT>
<SENT sid="6" pm="."><plain><z:mp ids='MP_0005048'>Thrombosis</z:mp> is the most frequent clinical manifestation of APS </plain></SENT>
<SENT sid="7" pm="."><plain>It involves many organs, resulting on multiorgan failure: this is the catastrophic APS </plain></SENT>
<SENT sid="8" pm="."><plain>The treatment is the same whether the APS is primary or secondary </plain></SENT>
<SENT sid="9" pm="."><plain>It is mainly symptomatic and consists in the prevention of <z:mp ids='MP_0005048'>thrombosis</z:mp> at short and long-term by using aspirin and/or <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>Immunomodulating treatment can be offered but its efficiency at long-term is unproven </plain></SENT>
<SENT sid="11" pm="."><plain>The mortality varies according to the etiology and the clinical manifestations </plain></SENT>
<SENT sid="12" pm="."><plain>The mortality rate is 50 percent in catastrophic APS, despite treatment </plain></SENT>
</text></document>